QUETIAPINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H25N3O2S
Molecular Weight	383.507
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCCOCCN1CCN(CC1)C2=NC3=C(SC4=C2C=CC=C4)C=CC=C3

InChI

InChIKey=URKOMYMAXPYINW-UHFFFAOYSA-N

InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2

HIDE SMILES / InChI

Molecular Formula	C21H25N3O2S
Molecular Weight	383.507
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022047s038lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12973385 | https://www.ncbi.nlm.nih.gov/pubmed/10839333

Quetiapine, marketed as SEROQUEL XR, is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and along with an antidepressant to treat major depressive disorder. The mechanism of action of SEROQUEL XR in the treatment of schizophrenia, bipolar disorder and major depressive disorder (MDD), is unknown. However, its efficacy in schizophrenia could be mediated through a combination of dopamine type 2 (D2) and serotonin type 2A (5HT2A) antagonism. The active metabolite, N-desalkyl quetiapine (norquetiapine), has similar activity at D2, but greater activity at 5HT2A receptors, than the parent drug (quetiapine). Quetiapine’s efficacy in bipolar depression and MDD may partly be explained by the high affinity and potent inhibitory effects that norquetiapine exhibits for the norepinephrine transporter. Antagonism at receptors other than dopamine and serotonin with similar or greater affinities may explain some of the other effects of quetiapine and norquetiapine: antagonism at histamine H1 receptors may explain the somnolence, antagonism at adrenergic α1b receptors may explain the orthostatic hypotension, and antagonism at muscarinic M1 receptors may explain the anticholinergic effects. Quetiapine and norquetiapine have affinity for multiple neurotransmitter receptors including dopamine D1 and D2, serotonin 5HT1A and 5HT2A, histamine H1, muscarinic M1, and adrenergic α1b and α2 receptors. Quetiapine differs from norquetiapine in having no appreciable affinity for muscarinic M1 receptors whereas norquetiapine has high affinity. Quetiapine and norquetiapine lack appreciable affinity for benzodiazepine receptors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 2a (5-HT2a) receptor 230 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16038601	Antagonist 2760
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10839333	Antagonist 2760

Conditions

Condition	Modality	Highest Phase	Product
Schizophrenia 295 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022047s038lbl.pdf	Primary	Approved 8360	SEROQUEL XR Approved Use 1.1 Schizophrenia. SEROQUEL XR is indicated for the treatment of schizophrenia. The efficacy of SEROQUEL XR in schizophrenia was established in one 6-week and one maintenance trial in adults with schizophrenia. Efficacy was supported by three 6 week trials in adults with schizophrenia and one 6-week trial in adolescents with schizophrenia (13-17 years) treated with SEROQUEL. 1.2 Bipolar Disorder SEROQUEL XR is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. The efficacy of SEROQUEL XR in manic or mixed episodes of bipolar I disorder was established in one 3-week trial in adults with manic or mixed episodes associated with bipolar I disorder. Efficacy was supported by two 12-week monotherapy trials and one 3-week adjunctive trial in adults with manic episodes associated with bipolar I disorder as well as one 3-week monotherapy trial in children and adolescents (10– 17 years) with manic episodes associated with bipolar I disorder treated with SEROQUEL. 1.3 Adjunctive Treatment of Major Depressive Disorder (MDD) ROQUEL XR is indicated for use as adjunctive therapy to antidepressants for the treatment of MDD. The efficacy of SEROQUEL XR as adjunctive therapy to antidepressants in MDD was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant treatment. Launch Date 1.17936003E12
Bipolar disorder 34 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022047s038lbl.pdf	Primary	Approved 8360	SEROQUEL XR Approved Use 1.1 Schizophrenia. SEROQUEL XR is indicated for the treatment of schizophrenia. The efficacy of SEROQUEL XR in schizophrenia was established in one 6-week and one maintenance trial in adults with schizophrenia. Efficacy was supported by three 6 week trials in adults with schizophrenia and one 6-week trial in adolescents with schizophrenia (13-17 years) treated with SEROQUEL. 1.2 Bipolar Disorder SEROQUEL XR is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. The efficacy of SEROQUEL XR in manic or mixed episodes of bipolar I disorder was established in one 3-week trial in adults with manic or mixed episodes associated with bipolar I disorder. Efficacy was supported by two 12-week monotherapy trials and one 3-week adjunctive trial in adults with manic episodes associated with bipolar I disorder as well as one 3-week monotherapy trial in children and adolescents (10– 17 years) with manic episodes associated with bipolar I disorder treated with SEROQUEL. 1.3 Adjunctive Treatment of Major Depressive Disorder (MDD) ROQUEL XR is indicated for use as adjunctive therapy to antidepressants for the treatment of MDD. The efficacy of SEROQUEL XR as adjunctive therapy to antidepressants in MDD was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant treatment. Launch Date 1.17936003E12
Major depressive disorder 172 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022047s038lbl.pdf	Palliative	Approved 8360	SEROQUEL XR Approved Use 1.1 Schizophrenia. SEROQUEL XR is indicated for the treatment of schizophrenia. The efficacy of SEROQUEL XR in schizophrenia was established in one 6-week and one maintenance trial in adults with schizophrenia. Efficacy was supported by three 6 week trials in adults with schizophrenia and one 6-week trial in adolescents with schizophrenia (13-17 years) treated with SEROQUEL. 1.2 Bipolar Disorder SEROQUEL XR is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. The efficacy of SEROQUEL XR in manic or mixed episodes of bipolar I disorder was established in one 3-week trial in adults with manic or mixed episodes associated with bipolar I disorder. Efficacy was supported by two 12-week monotherapy trials and one 3-week adjunctive trial in adults with manic episodes associated with bipolar I disorder as well as one 3-week monotherapy trial in children and adolescents (10– 17 years) with manic episodes associated with bipolar I disorder treated with SEROQUEL. 1.3 Adjunctive Treatment of Major Depressive Disorder (MDD) ROQUEL XR is indicated for use as adjunctive therapy to antidepressants for the treatment of MDD. The efficacy of SEROQUEL XR as adjunctive therapy to antidepressants in MDD was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant treatment. Launch Date 1.17936003E12

C_max

Value	Dose	Analyte	Population
58.23 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25025989	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	QUETIAPINE FUMARATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
60.11 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25025989	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	QUETIAPINE FUMARATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
58.42 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25025989	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	QUETIAPINE FUMARATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

AUC

Value	Dose	Analyte	Population
187.44 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25025989	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	QUETIAPINE FUMARATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
190.39 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25025989	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	QUETIAPINE FUMARATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
197.55 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25025989	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	QUETIAPINE FUMARATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
3.86 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25025989	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	QUETIAPINE FUMARATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.98 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25025989	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	QUETIAPINE FUMARATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.85 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25025989	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	QUETIAPINE FUMARATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
17% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020639s070lbl.pdf	unknown, unknown		QUETIAPINE FUMARATE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
800 mg single, oral Highest studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/24385309/	unhealthy, 18 - 60 years n = 14 Health Status: unhealthy Condition: schizophrenia Age Group: 18 - 60 years Sex: M+F Population Size: 14 Sources: https://pubmed.ncbi.nlm.nih.gov/24385309/	Other AEs: Somnolence, Dizziness... Other AEs: Somnolence (13 patients) Dizziness (10 patients) Constipation (4 patients) Tongue paralysis (1 patient) Dry mouth (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/24385309/
24 g single, oral Overdose Dose: 24 g Route: oral Route: single Dose: 24 g Sources: https://pubmed.ncbi.nlm.nih.gov/18433934/	unknown, 18 - 84 years n = 945 Health Status: unknown Condition: abuse Age Group: 18 - 84 years Sex: M+F Population Size: 945 Sources: https://pubmed.ncbi.nlm.nih.gov/18433934/	Disc. AE: Drowsiness, Tachycardia... AEs leading to discontinuation/dose reduction: Drowsiness (76%) Tachycardia (56%) Hypotension (18%) Coma (10%) Agitation (6%) Respiratory depression (5%) Seizures (2%) Electrocardiogram QTc interval prolonged (4%) Death (grade 5, 3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/18433934/
750 mg 1 times / day steady, oral Highest studied dose Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9193196/	unhealthy, 20 - 61 years n = 96 Health Status: unhealthy Condition: schizophrenia Age Group: 20 - 61 years Sex: M+F Population Size: 96 Sources: https://pubmed.ncbi.nlm.nih.gov/9193196/	Other AEs: Agitation, Somnolence... Other AEs: Agitation (26 patients) Somnolence (24 patients) Headache (18 patients) Dizziness (11 patient) Constipation (11 patient) Insomnia (10 patients) Tachycardia (7 patients) Pain (7 patients) Pharyngitis (7 patients) Rash (7 patients) Alanine aminotransferase increased (6 patients) Dry mouth (6 patients) Dyspepsia (6 patients) Nausea (6 patients) Asthenia (5 patients) Vomiting (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/9193196/
24.4 g single, oral Overdose Dose: 24.4 g Route: oral Route: single Dose: 24.4 g Sources: https://pubmed.ncbi.nlm.nih.gov/24199644/	unknown, 22 - 49 years n = 9 Health Status: unknown Age Group: 22 - 49 years Sex: M+F Population Size: 9 Sources: https://pubmed.ncbi.nlm.nih.gov/24199644/	Disc. AE: Somnolence, Tachycardia... AEs leading to discontinuation/dose reduction: Somnolence (9 patients) Tachycardia (9 patients) Respiratory depression (9 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/24199644/
15 g single, oral Overdose Dose: 15 g Route: oral Route: single Dose: 15 g Co-administed with:: lithium Sources: https://pubmed.ncbi.nlm.nih.gov/21070111/	unhealthy, 32 years n = 1 Health Status: unhealthy Condition: bipolar disorder Age Group: 32 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/21070111/	Disc. AE: Postural hypotension, Sinus tachycardia... AEs leading to discontinuation/dose reduction: Postural hypotension (1 patient) Sinus tachycardia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/21070111/
400 mg 2 times / day steady, oral (max) Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20831551/	unhealthy, 40 - 72 years n = 5 Health Status: unhealthy Condition: schizophrenia Age Group: 40 - 72 years Sex: M+F Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/20831551/	Disc. AE: Bladder distension... AEs leading to discontinuation/dose reduction: Bladder distension (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/20831551/
1.2 g single, oral Overdose Dose: 1.2 g Route: oral Route: single Dose: 1.2 g Co-administed with:: alcohol smoking cocaine Sources: https://pubmed.ncbi.nlm.nih.gov/28207421/	unknown, 45 years n = 1 Health Status: unknown Condition: abuse, hypertension, type 2 diabetes mellitus, and schizoaffective disorder Age Group: 45 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/28207421/	Disc. AE: LBBB... AEs leading to discontinuation/dose reduction: LBBB (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/28207421/
600 mg 1 times / day steady, oral (max) MTD Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24963729/	unhealthy, adult n = 15 Health Status: unhealthy Condition: cannabis dependence Age Group: adult Sex: unknown Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/24963729/	Other AEs: Fatigue, Somnolence... Other AEs: Fatigue (80%) Somnolence (47%) Sources: https://pubmed.ncbi.nlm.nih.gov/24963729/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1579 substrate 1709	inhibitor 1752	inhibitor 1837 substrate 1193	inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1509 CYP2C19 1463 L-type Ca2+ channels 26 BCRP 691	P-gp 1527

Drug as perpetrator

Target	Modality	Activity
L-type Ca2+ channels 28	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/21300721/	yes [IC50 16.9 uM]
BCRP 765	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/18834354/	yes [IC50 66.1 uM]
CYP1A2 1673	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020639ap_Seroquel_phrmrP1.pdf Page: 59.0	yes [Inhibition 150 uM]
CYP2C19 1537	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020639ap_Seroquel_phrmrP1.pdf Page: 59.0	yes [Inhibition 30 uM]
CYP2C9 1803	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020639ap_Seroquel_phrmrP1.pdf Page: 59.0	yes [Inhibition 30 uM]
CYP2D6 1875	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020639ap_Seroquel_phrmrP1.pdf Page: 59.0	yes [Inhibition 30 uM]
CYP3A4 1909	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20639se1-017,016_seroquel_lbl.pdf Page: 3.0	yes [Inhibition 30 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 1527	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/22525746/	yes [Km 12.3 uM]
CYP2D6 1193	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20639se1-017,016_seroquel_lbl.pdf Page: 60.0	yes
CYP3A4 1709	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20639se1-017,016_seroquel_lbl.pdf Page: 4.0	yes	yes (co-administration study) Comment: all metabolites (5) formed from CYP3A4 metabolism; ketoconazole reduces clearance by 84%, increasing maximum plasma concentration by 335%; phenytoin increases clearance by 5-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20639se1-017,016_seroquel_lbl.pdf Page: 4.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://pubmed.ncbi.nlm.nih.gov/21300721/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:8707	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8707
ChemicalBook	CB6270450	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6270450
ChemicalBook	CB82709002	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB82709002
MolPort	MolPort-002-506-329	https://www.molport.com/shop/molecule-link/MolPort-002-506-329
ZINC	ZINC000019632628	http://zinc15.docking.org/substances/ZINC000019632628
eMolecules	31227816	https://www.emolecules.com/cgi-bin/more?vid=31227816

PubMed

Title	Date	PubMed
Tolerability profile of atypical antipsychotics in children and adolescents.	2001	11772153
Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?	2001	11735674
Review of atypical antipsychotics and weight gain.	2001	11603886
Hyperglycemia associated with the use of atypical antipsychotics.	2001	11603883
Clinical pharmacokinetics of quetiapine: an atypical antipsychotic.	2001	11510628
Failed challenge with quetiapine after neuroleptic malignant syndrome with conventional antipsychotics.	2001 Aug	11718487
The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia.	2001 Aug	11514134
In vivo 5-HT2A receptor blockade by quetiapine: an R91150 single photon emission tomography study.	2001 Aug	11512044
Novel antipsychotics and severe hyperlipidemia.	2001 Aug	11476120
Management of psychosis in Parkinson's disease.	2001 Aug	11470967
Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.	2001 Aug 17	11513838
Novel antipsychotics and acute dystonic reactions.	2001 Dec	11806865
Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach.	2001 Dec	11735847
Broad therapeutic uses of atypical antipsychotic medications.	2001 Dec 1	11743945
Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.	2001 Dec 1	11743942
Long-term remission of schizophrenia in an adolescent treated with quetiapine.	2001 Fall	11642479
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.	2001 Feb 1	11462978
Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence.	2001 Jan	11527002
Treatment of the agitation of late-life psychosis and Alzheimer's disease.	2001 Jan	11520475
Acute neutropenia in a patient treated with quetiapine.	2001 Jul-Aug	11496032
Use of quetiapine in delirium: case reports.	2001 Jul-Aug	11496025
Ziprasidone: a new atypical antipsychotic.	2001 Jun	11585006
[Clinical and pharmacological studies of the second generation antipsychotics].	2001 Nov	11813688
Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.	2001 Nov	11691681
Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects.	2001 Nov	11682246
[Quetiapine poisoning].	2001 Nov 17	11714478
Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.	2001 Nov 2	11711053
A 25-year-old woman with bipolar disorder, 1 year later.	2001 Nov 28	11722274
Ziprasidone: profile on safety.	2001 Oct	11825308
Antipsychotic medication: effects on regulation of glucose and lipids.	2001 Oct	11825300
Agranulocytosis and granulocytopenia associated with quetiapine.	2001 Oct	11722307
Cognitive improvements in psychotic subjects treated with "Seroquel" (quetiapine fumarate): an exploratory study.	2001 Oct	11593079
Quetiapine: efficacy and tolerability in schizophrenia.	2001 Oct	11587888
Quetiapine--efficacy in different domains.	2001 Oct	11587885
Quetiapine-related tardive dyskinesia.	2001 Oct	11579018
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.	2001 Oct	11561066
Atypical antipsychotics: impaired glucose metabolism.	2001 Oct 2	11599340
Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation.	2001 Oct 5	11675034
A case of depersonalization-derealization syndrome during treatment with quetiapine.	2001 Sep	11565631
Priapism from quetiapine overdose: first report and proposal of mechanism.	2001 Sep	11549503
Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database.	2001 Sep	11532730
Effects of newer antipsychotics on extrapyramidal function.	2002	11772117
Quetiapine and cataracts.	2002 Feb	11823292
Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.	2002 Feb	11823257
Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.	2002 Jan	11833834
Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.	2002 Jan	11800505
Neuroleptic malignant syndrome and quetiapine.	2002 Jan	11772710
EEG abnormalities during treatment with typical and atypical antipsychotics.	2002 Jan	11772698
Does cognitive function improve with quetiapine in comparison to haloperidol?	2002 Jan 15	11738537
[Drug-induced akathisia].	2002 Jan 19	11826669

Patents

Sample Use Guides

In Vivo Use Guide

Schizophrenia- Adults: Day 1: 300 mg/day Dose increases can be made at intervals as short as 1 day and in increments of up to 300 mg/day Schizophrenia-Adolescents: (13 to 17 years): Day 1: 50 mg/day; Day 2: 100 mg/day; Day 3: 200 mg/day; Day 4: 300 mg/day; Day 5: 400 mg/day; Bipolar I Disorder manic or mixed-Acute monotherapy or adjunct to lithium or divalproex-Adults: Day 1: 300 mg/day; Day 2: 600 mg/day; Day 3: between 400 and 800 mg/day. Major Depressive Disorder Adjunctive Therapy with Antidepressants: Adults: Day 1: 50 mg/day; Day 2: 50 mg/day; Day 3: 150 mg/day Bipolar I Disorder, manic Acute monotherapy: Children and Adolescents (10 to 17 years) : Day 1: 50 mg/day; Day 2: 100 mg/day; Day 3: 200 mg/day; Day 4: 300 mg/day; Day 5: 400 mg/day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Thu Jul 06 22:46:28 UTC 2023` Edited by `admin` on `Thu Jul 06 22:46:28 UTC 2023`
Record UNII	BGL0JSY5SI
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

QUETIAPINE

Official Name

English

QUETIAPINE [MI]

Common Name

English

quetiapine [INN]

Common Name

English

QUETIAPINE EXTENDED RELEASE

Common Name

English

Quetiapine [WHO-DD]

Common Name

English

QUETIAPINE [VANDF]

Common Name

English

ETHANOL, 2-(2-(4-DIBENZO(B,F)(1,4)THIAZEPIN-11-YL-1-PIPERAZINYL)ETHOXY)-

Systematic Name

English

NORSIC

Brand Name

English

QUETIAPINE [HSDB]

Common Name

English

NSC-758918

Code

English

2-(2-(4-DIBENZO(B,F)(1,4)THIAZEPIN-11-YLPIPERAZIN-1-YL)ETHOXY)ETHANOL

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66885